Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

Autor: Leopoldo Pérez de Isla, Raquel Arroyo-Olivares, Rodrigo Alonso, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz, Daniel Zambón, Francisco Fuentes, Nelva Mata, Mar Piedecausa, M. Dolores Mañas, Juan F. Sánchez Muñoz-Torrero, José Pablo Miramontes-González, Raimundo de Andrés, Marta Mauri, Rocío Aguado, Ángel Brea, José M. Cepeda, José I. Vidal-Pardo, Ceferino Martínez-Faedo, Miguel Ángel Barba, Rosa Argüeso, Enrique Ruiz-Pérez, Alfredo Michán, Francisco Arrieta, María Riestra Fernández, Leire Pérez, José M. Pinilla, Gonzalo Díaz-Soto, Xavier Pintó, Teresa Padró, Lina Badimón, Pedro Mata, Begoña Perez-Corral, Fátima Almagro, Raquel Arroyo, Adriana Saltijeral, Daniel Mosquera, Marta Casañas, Julio Carbayo, Jose María Cepeda, Raimundo De Andrés, José L. Díaz, Marta Diéguez, María Riestra, José López-Miranda, Jesús Galiana, Jesús García-Cruces, Juan Antonio Garrido, Luis Irigoyen, Pedro L. Martínez, Lorena Suárez, Rosa M. Borrallo, Juan Diego Mediavilla, Fernando Jaén, Pablo González, Patricia Rubio, Pablo Miramontes, Juan L. Morera, Ovidio Muñiz, Aurora González, Francisca Pereyra, José Pastor, José Miguel Pinilla, Manuel J. Romero, Enrique Ruiz, M. Pilar Álvarez, Pedro Sáenz, Juan F. Sánchez, Consuelo Sanz, Jose I. Vidal
Rok vydání: 2020
Předmět:
Zdroj: REVISTA ESPANOLA DE CARDIOLOGIA
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
ISSN: 0300-8932
Popis: Introduction and objectives: The SAFEHEART study was designed to analyze the situation of familial heterozygous hypercholesterolemia (FHH) and improve knowledge of this disease in Spain. Our objective was to determine the incidence rate of cardiovascular events, the estimated risk of developing an event and its modification, the use of lipid-lowering treatment, and the achievement of low-density lipoprotein cholesterol targets in patients with FHH. Methods: SAFEHEART is a prospective, open, multicenter, nationwide cohort study, with long-term protocol-based follow-up in a population of individuals with molecularly-characterized FHH. We analyzed patients older than 18 years with complete follow-up. Results: We included 2648 patients with FHH. The median follow-up was 6.6 (4.8-9.7) years. The overall incidence rate of cardiovascular events was 1.3 events/100 patient-years. After the follow-up, the 10-year estimated risk of developing a cardiovascular event was reduced from 1.6% to 1.3% (P
Databáze: OpenAIRE